Effective highly active antiretroviral therapy in patients with primary HIV-1 infection prevents the evolution of the avidity of HIV-1-specific antibodies

Journal of Acquired Immune Deficiency Syndromes

Volumn 46, Issue 2, 2007, Pages 145-150

  Selleri, Marina ^a   Orchi, Nicoletta ^a   Zaniratti, Maria Stefania ^a   Bellagamba, Rita ^a   Corpolongo, Angela ^a   Angeletti, Claudio ^a   Ippolito, Giuseppe ^a   Capobianchi, Maria Rosaria ^a   Girardi, Enrico ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

Antibody avidity; Antigen antibody reactions; Highly active antiretroviral therapy; Primary HIV 1 infection; Viral replication

Indexed keywords

ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; BINDING AFFINITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG WITHDRAWAL; EVOLUTION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; MULTIPLE CYCLE TREATMENT; PLASMA; PRIORITY JOURNAL; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; VIREMIA; VIRUS REPLICATION; WESTERN BLOTTING;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIBODY AFFINITY; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 34748856217     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318120039b     Document Type: Article

References (23)

1. Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS. 2003;17:1871-1879.
2. Le Guillou H, Le Meur A, Bourdon S, et al. Avidites des anticorps: application au diagnostic d'infection récente à VIH. Ann Biol Clin (Paris). 2001;59:41-47.
3. Suligoi B, Galli C, Massi M, et al. Precision and accuracy of a procedure for detecting recent human immunodeficiency virus infections by calculating the antibody avidity index by an automated immunoassay-based method. J Clin Microbiol. 2002;40:4015-4020.
4. Suligoi B, Massi M, Galli C, et al. Identifying recent HIV infections using the Avidity Index and an automated enzyme immunoassay. J Acquir Immune Defic Syndr. 2003;32:424-428.
5. Janssen RS, Satten GA, Stramer SL, et al. New testing strategy to detect early HIV-1 infection for use in incident estimate for clinical and prevention purposes. JAMA. 1998;280:42-48.
6. Markowitz M, Vesanen M, Tenner-Racz K, et al. The effects of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. J Infect Dis. 1999;179:527-537.
7. Binley JM, Trkola A, Ketas T, et al. The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type I infection. J Infect Dis. 2000;182:945-949.
8. Rosemberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. Nature. 2000;407:523-526.
9. Kaufmann GR, Bloch M, Zaunders JJ, et al. Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy. AIDS. 2000;14:959-969.
10. Lacabaratz-Porret C, Urrutia A, Doisne JM, et al. Impact of antiretroviral therapy and changes in viral load on human immunodeficiency virus (HIV)-specific T cell responses in primary HIV infection. J Infect Dis. 2003;187:748-757.
11. Zaunders JJ, Cunningham PH, Kelleher AD, et al. Potent antiretroviral therapy of primary human immunodeficiency virus type (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV DNA despite clearance of plasma viremia. J Infect Dis. 1999;180:320-329.
12. Lafeuillade A, Poggi C, Tamalet C, et al. Effects of a combination of zidovudine, didanosine, and lamivudine on primary human immunodeficiency virus type 1 infection. J Infect Dis. 1997;175:1051-1055.
13. Morris BL, Binley JM, Clas BA, et al. HIV-1 antigen-specific and nonspecific B cell responses are sensitive to combination antiretroviral therapy. J Exp Med. 1998;188:233-245.
14. Jurriaans S, Sankatsing SUC, Prins JM, et al. HIV-1 seroreversion in an HIV-1 seropositive patient treated during acute infection with highly active antiretroviral therapy and mycophenolate mofetil. AIDS. 2004;18:1607-1608.
15. Kassutto S, Johnston MN, Rosemberg ES. Incomplete HIV type 1 antibody evolution and seroreversion in acutely infected individuals treated with early antiretroviral therapy. Clin Infect Dis. 2005;40:868-873.
16. Hare CB, Pappalardo BL, Busch MP, et al. Seroreversion in subjects receiving antiretroviral therapy during acute/early HIV infection. Clin Infect Dis. 2006;42:700-708.
17. Amor A, Toro C, Jimenez V, et al. Seroreversion of HIV antibodies in patients with prolonged suppression of viremia under HAART. AIDS. 2006;20:1460-1462.
18. Hainaut M, Peltier CA, Gerard M, et al. Effectiveness of antiretroviral therapy initiated before the age of 2 months in infants vertically infected with human immunodeficiency virus type 1. Eur J Pediatr. 2000;159:778-782.
19. Luzuriaga K, Bryson Y, Krogstad P, et al. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. N Engl J Med. 1997;336:1343-1349.
20. Le Guillou-Guillemette H, Renier G, Vielle B, et al. Immune restoration under HAART in patients chronically infected with HIV-1: diversity of T, B, and NK immune responses. Viral Immunol. 2006;19:267-276.
21. Adalid-Peralta L, Grangeot-Keros L, Rudent A, et al. Impact of highly active antiretroviral therapy on the maturation of anti-HIV-1 antibodies during primary HIV-1 infection. HIV Med. 2006;7:514-519.
22. Pullen GR, Fitzgerald MG, Hoskiing CS. Antibody avidity determination by ELISA using thiocyanate elution. J Immunol Methods. 1986;86:83-87.
23. Pereira Arias-Bouda LM, Kuijper S, Van der Werf A, et al. Changes in avidity and level of immunoglobulin G antibodies to Mycobacterium tuberculosis in sera of patients undergoing treatment for pulmonary tuberculosis. Clin Diagn Lab Immunol. 2003;10:702-709.